Recruiting
Phase 2

JAK Inhibitors

Sponsor:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Code:

NCT05743244

Conditions

Diabetes Mellitus, Type 1

Eligibility Criteria

Sex: All

Age: 12 - 35

Healthy Volunteers: Not accepted

Interventions

Abrocitinib 200 MG Oral Tablet

Ritlecitinib

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information